More than 30 percent of all human cancers—including 95 percent of pancreatic cancers and 45 percent of colorectal cancers—are driven by mutations in RAS genes.
RAS in Cancer and Disease
Our goal is to understand how RAS proteins are regulated and how they activate downstream effector pathways.
Mutations in the RAS pathway drive cancer and common developmental disorders, including Noonan syndrome, neurofibromatosis type 1, and autism. A deep understanding of this pathway is crucial for treating these diseases.
Explore our research focus areas →